Related Experiment Video
Updated: Nov 28, 2025
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
888
Long non-coding RNAs: Emerging regulators for chemo/immunotherapy resistance in cancer stem cells
Chongyang Shen1, Chuan Yang2, Bing Xia3
1Basic Medicine School, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China; Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Anhui, 230038, China.
Cancer Letters
|November 26, 2020
Summary
Long non-coding RNAs (lncRNAs) sustain cancer stem cell (CSC) stemness, driving resistance to chemotherapy and immunotherapy. Targeting lncRNAs offers a promising strategy to overcome treatment resistance in cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer stem cells (CSCs) drive tumor development and therapeutic resistance.
- CSCs exhibit self-renewal, contributing to resistance against chemotherapy and immunotherapy.
- Understanding CSC regulatory mechanisms is crucial for overcoming treatment resistance.
Purpose of the Study:
- To summarize the regulatory role of long non-coding RNAs (lncRNAs) in CSC stemness.
- To elucidate mechanisms of lncRNA-mediated chemo- and immune-resistance in CSCs.
- To discuss future research directions for CSC-targeted therapies.
Main Methods:
- Literature review of recent studies on lncRNAs and CSCs.
- Analysis of lncRNA regulatory roles in CSC stemness.
- Discussion of mechanisms underlying CSC resistance.
Main Results:
- lncRNAs are key regulators sustaining CSC stemness.
- lncRNAs contribute to chemo- and immune-resistance in CSCs.
- Specific lncRNAs modulate CSC behavior and therapeutic response.
Conclusions:
- lncRNAs play a critical role in maintaining CSC properties and therapeutic resistance.
- Targeting lncRNAs presents a potential strategy to enhance cancer treatment efficacy.
- Further research into lncRNA functions can guide novel CSC-targeted therapies.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
9.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.5K
02:39lncRNA - Long Non-coding RNAs
3.2K
3.2K
02:40Cancer Stem Cells and Tumor Maintenance
5.4K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.4K
02:53Adaptive Mechanisms in Cancer Cells
6.4K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.4K
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
01:22MicroRNAs
3.5K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.5K